JP2001515029A - 粒状分散形態の固形医薬剤形 - Google Patents

粒状分散形態の固形医薬剤形

Info

Publication number
JP2001515029A
JP2001515029A JP2000509400A JP2000509400A JP2001515029A JP 2001515029 A JP2001515029 A JP 2001515029A JP 2000509400 A JP2000509400 A JP 2000509400A JP 2000509400 A JP2000509400 A JP 2000509400A JP 2001515029 A JP2001515029 A JP 2001515029A
Authority
JP
Japan
Prior art keywords
drug
water
particulate
polymer
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000509400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515029A5 (cg-RX-API-DMAC10.html
Inventor
イサーク・ゲイバー−セラシエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2001515029A publication Critical patent/JP2001515029A/ja
Publication of JP2001515029A5 publication Critical patent/JP2001515029A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2000509400A 1997-08-21 1998-07-29 粒状分散形態の固形医薬剤形 Abandoned JP2001515029A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5619597P 1997-08-21 1997-08-21
US60/056,195 1997-08-21
PCT/US1998/015693 WO1999008660A1 (en) 1997-08-21 1998-07-29 Solid pharmaceutical dosage forms in form of a particulate dispersion

Publications (2)

Publication Number Publication Date
JP2001515029A true JP2001515029A (ja) 2001-09-18
JP2001515029A5 JP2001515029A5 (cg-RX-API-DMAC10.html) 2006-01-05

Family

ID=22002810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000509400A Abandoned JP2001515029A (ja) 1997-08-21 1998-07-29 粒状分散形態の固形医薬剤形

Country Status (17)

Country Link
US (1) US20010048946A1 (cg-RX-API-DMAC10.html)
EP (1) EP1011640A1 (cg-RX-API-DMAC10.html)
JP (1) JP2001515029A (cg-RX-API-DMAC10.html)
KR (1) KR20010023085A (cg-RX-API-DMAC10.html)
AR (1) AR018252A1 (cg-RX-API-DMAC10.html)
AU (1) AU8600098A (cg-RX-API-DMAC10.html)
BR (1) BR9811972A (cg-RX-API-DMAC10.html)
CA (1) CA2292586C (cg-RX-API-DMAC10.html)
CO (1) CO4960652A1 (cg-RX-API-DMAC10.html)
GT (1) GT199800136A (cg-RX-API-DMAC10.html)
HN (1) HN1998000115A (cg-RX-API-DMAC10.html)
NZ (1) NZ502869A (cg-RX-API-DMAC10.html)
PA (1) PA8458101A1 (cg-RX-API-DMAC10.html)
PE (1) PE109599A1 (cg-RX-API-DMAC10.html)
SV (1) SV1998000104A (cg-RX-API-DMAC10.html)
WO (1) WO1999008660A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA987551B (cg-RX-API-DMAC10.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513037A (ja) * 2001-11-20 2005-05-12 スミスクライン ビーチャム パブリック リミテッド カンパニー 5−[4−[2−(n−メチル−n−(2−ピリジル)アミノ)エトキシ]ベンジル]チアゾリジン−2,4−ジオンおよび当該化合物配合の医薬組成物
JP2008525335A (ja) * 2004-12-24 2008-07-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト 経口投与できる固体の放出改変型医薬投与形
JP2008540540A (ja) * 2005-05-10 2008-11-20 ノバルティス アクチエンゲゼルシャフト 圧縮性に乏しい治療用化合物を有する組成物の製造法
JP2011526928A (ja) * 2008-07-03 2011-10-20 ノバルティス アーゲー 溶融造粒方法
JP2014526508A (ja) * 2011-09-14 2014-10-06 セルジーン コーポレイション シクロプロパンカルボン酸{2−[(1s)−1−(3−エトキシ−4−メトキシ−フェニル)−2−メタンスルホニル−エチル]−3−オキソ−2,3−ジヒドロ−1h−イソインドール−4−イル}−アミドの製剤

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
JPH06511291A (ja) * 1991-08-02 1994-12-15 ウィルコム タフティング ピーティーワイ リミテッド 房付け方法及び房付けシステム
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2002024168A1 (fr) * 2000-09-25 2002-03-28 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide medicinale
ATE293439T1 (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
MXPA03011784A (es) 2001-06-22 2004-04-02 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros.
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
CN1681479A (zh) * 2002-08-12 2005-10-12 辉瑞产品公司 半有序药物和聚合物的药物组合物
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050100608A1 (en) * 2003-02-21 2005-05-12 Watson Pharmaceuticals, Inc. Testosterone oral dosage formulations and associated methods
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
US8273371B2 (en) * 2003-06-27 2012-09-25 Johan Adriaan Martens Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
RU2331410C2 (ru) * 2003-12-04 2008-08-20 Пфайзер Продактс Инк. Способ получения фармацевтических мультичастиц
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1817008B1 (en) 2004-11-09 2020-04-01 Board of Regents, The University of Texas System Stabilized hme composition with small drug particles
DK1830817T3 (da) * 2004-12-30 2013-04-02 Pf Medicament Stabil, fast dispersion af et derivat af vinca-alkaloid og fremgangsmåde til fremstilling heraf
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
FR2880274B1 (fr) * 2004-12-30 2007-04-13 Pierre Fabre Medicament Sa Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
JP2010513324A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬化合物および医薬組成物
WO2010136604A1 (en) * 2009-05-29 2010-12-02 Dsm Ip Assets B.V. Transfer matrix for transferring a bioactive agent to body tissue
CN103391769A (zh) 2011-02-17 2013-11-13 霍夫曼-拉罗奇有限公司 通过热熔挤出使活性药物成分从过冷液体状态受控结晶的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンa物質含有易溶性固形製剤
JPH054919A (ja) * 1990-07-25 1993-01-14 Sankyo Co Ltd チアゾリジン誘導体の固体分散体
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
SG43179A1 (en) * 1991-12-18 1997-10-17 Warner Lambert Co A process for the prepatation of a solid dispersion
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
JPH07324086A (ja) * 1994-05-31 1995-12-12 Sankyo Co Ltd チアゾリジン誘導体の固体分散体または固体分散体製剤
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513037A (ja) * 2001-11-20 2005-05-12 スミスクライン ビーチャム パブリック リミテッド カンパニー 5−[4−[2−(n−メチル−n−(2−ピリジル)アミノ)エトキシ]ベンジル]チアゾリジン−2,4−ジオンおよび当該化合物配合の医薬組成物
JP2008525335A (ja) * 2004-12-24 2008-07-17 バイエル・ヘルスケア・アクチェンゲゼルシャフト 経口投与できる固体の放出改変型医薬投与形
JP2008540540A (ja) * 2005-05-10 2008-11-20 ノバルティス アクチエンゲゼルシャフト 圧縮性に乏しい治療用化合物を有する組成物の製造法
JP2011526928A (ja) * 2008-07-03 2011-10-20 ノバルティス アーゲー 溶融造粒方法
JP2014526508A (ja) * 2011-09-14 2014-10-06 セルジーン コーポレイション シクロプロパンカルボン酸{2−[(1s)−1−(3−エトキシ−4−メトキシ−フェニル)−2−メタンスルホニル−エチル]−3−オキソ−2,3−ジヒドロ−1h−イソインドール−4−イル}−アミドの製剤
JP2017105804A (ja) * 2011-09-14 2017-06-15 セルジーン コーポレイション シクロプロパンカルボン酸{2−[(1s)−1−(3−エトキシ−4−メトキシ−フェニル)−2−メタンスルホニル−エチル]−3−オキソ−2,3−ジヒドロ−1h−イソインドール−4−イル}−アミドの製剤
JP2017178961A (ja) * 2011-09-14 2017-10-05 セルジーン コーポレイション シクロプロパンカルボン酸{2−[(1s)−1−(3−エトキシ−4−メトキシ−フェニル)−2−メタンスルホニル−エチル]−3−オキソ−2,3−ジヒドロ−1h−イソインドール−4−イル}−アミドの製剤

Also Published As

Publication number Publication date
CA2292586C (en) 2006-02-14
GT199800136A (es) 2000-02-11
KR20010023085A (ko) 2001-03-26
BR9811972A (pt) 2000-08-15
PE109599A1 (es) 1999-12-19
ZA987551B (en) 1999-02-23
HN1998000115A (es) 1999-06-02
SV1998000104A (es) 1999-07-02
PA8458101A1 (es) 2001-12-14
CO4960652A1 (es) 2000-09-25
AR018252A1 (es) 2001-11-14
WO1999008660A1 (en) 1999-02-25
NZ502869A (en) 2002-10-25
AU8600098A (en) 1999-03-08
EP1011640A1 (en) 2000-06-28
CA2292586A1 (en) 1999-02-25
US20010048946A1 (en) 2001-12-06

Similar Documents

Publication Publication Date Title
CA2292586C (en) Solid pharmaceutical dosage forms in form of a particulate dispersion
JP3696087B2 (ja) イトラコナゾール(itraconazole)経口用製剤及びその製造方法
TWI389691B (zh) 可口服且具有活性成分快速釋出之固態醫藥劑型
EP1487416B1 (en) Drug microparticles
US6677362B1 (en) Solid pharmaceutical dispersions
CA2166891C (en) Method for making freeze dried drug dosage forms
JP5610165B2 (ja) ナテグリニド含有製剤
JP2001511156A (ja) 高いバイオアベイラビリティーを有するフェノフィブレート医薬組成物及びそれを調製するための方法
JP2018502160A (ja) 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体
WO1996041628A1 (en) Granules containing pranlukast, process for producing the granules, and method of lowering cohesiveness of pranlukast
JP2003516354A (ja) 生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物
Tripathy et al. Solid dispersion: A technology for improving aqueous solubility of drug
MX2007005427A (es) Composicion de dispersion solida de pranlukast con biodisponibilidad mejorada y metodo para preparar la dispersion solida.
Tran et al. Solubilization of poorly water-soluble drugs using solid dispersions
MXPA04008137A (es) Preparaciones de liberacion sostenida y procedimiento para producir las mismas.
JP5980449B2 (ja) 非晶質なシロスタゾールを含有する固体分散体
TWI436765B (zh) 用於治療hcv感染之醫藥組合物
JP2000507991A (ja) 即時放出薬剤送達形態
JP6072705B2 (ja) 固体分散体製剤
EP4251155A1 (en) Improved wet granulation processes for apixaban comprising formulations
MXPA99011317A (en) Solid pharmaceutical dosage forms in form of a particulate dispersion
TW202604488A (zh) 包含索托克拉固體分散體之醫藥調配物及其製備方法
HK1069126B (en) Drug microparticles
HK1134236A (en) Drug microparticles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050721

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20070316